Plus Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting
Plus Therapeutics (Nasdaq: PSTV) announced its participation at the AACR 2022 Annual Meeting, presenting a poster on a biology-based model predicting recurrent glioblastoma response to treatment with 186Re-labeled nanoliposomes. The poster will be showcased on April 12, 2022, from 9:00 a.m. to 12:30 p.m. CT at the New Orleans Convention Center. Plus Therapeutics focuses on innovative cancer therapies using advanced nanotechnology for drug delivery. The company is committed to developing effective treatments for patients with difficult-to-treat cancers.
- Participation in a prestigious conference like AACR, enhancing visibility.
- Presentation of novel research on glioblastoma, indicating ongoing innovation in treatment methods.
- None.
AUSTIN, Texas, April 08, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced that the company will present a poster at the upcoming American Association for Cancer Research (AACR) 2022 Annual Meeting, which is being held April 8-13, 2022, in New Orleans, La., and virtually.
Details of the poster presentation
Title: A biology-based, mathematical model to predict the response of recurrent glioblastoma to treatment with 186Re-labeled nanoliposomes
Session Title: Mathematical Models
Session Date and Time: Tuesday, April 12, 2022, 9:00 a.m. – 12:30 p.m. CT
Location: New Orleans Convention Center, Exhibit Halls D – H, Poster Section 29
Poster Board Number: 13
Permanent Abstract Number: 2742
Link to Abstract: https://www.abstractsonline.com/pp8/#!/10517/presentation/18391
A copy of the poster presentation will be made available under the Presentations tab of the For Investors section of the Company’s website following the meeting at www.plustherapeutics.com.
About Plus Therapeutics
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on the development, manufacture, and commercialization of complex and innovative treatments for patients battling cancer and other life-threatening diseases.
Our proprietary nanotechnology platform is currently centered around the enhanced delivery of a variety of drugs using novel liposomal encapsulation technology. Liposomal encapsulation has been extensively explored and undergone significant technical and commercial advances since it was first developed. Our platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements in this press release other than statements of historical fact are forward-looking statements. These forward-looking statements may be identified by future verbs, as well as terms such as “designed to,” “will,” “can,” “potential,” “focus,” “preparing,” “next steps,” “possibly,” and similar expressions or the negatives thereof. Such statements are based upon certain assumptions and assessments made by management in light of their experience and their perception of historical trends, current conditions, expected future developments and other factors they believe to be appropriate. These statements include, without limitation, statements regarding the following: the potential promise of 186RNL including the ability of 186RNL to safely and effectively deliver radiation directly to the tumor at high doses; expectations as to the Company’s future performance including the next steps in developing the Company’s current assets; the Company’s clinical trials including statements regarding the timing and characteristics of the ReSPECT-LM or the ReSPECT-PBC trials; possible negative effects of 186RNL; the continued evaluation of 186RNL including through evaluations via a seventh patient cohort; and the intended functions of the Company’s platform and expected benefits from such functions.
The forward-looking statements included in this press release are subject to a number of risks and uncertainties that may cause actual results to differ materially from those discussed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the Company’s actual results may differ, including materially, from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to, the following: the early stage of the Company’s product candidates and therapies, the results of the Company’s research and development activities, including uncertainties relating to the clinical trials of its product candidates and therapies; the Company’s liquidity and capital resources and its ability to raise additional cash, the outcome of the Company’s partnering/licensing efforts, risks associated with laws or regulatory requirements applicable to it, market conditions, product performance, litigation or potential litigation, and competition within the regenerative medicine field, among others; and additional risks described under the heading “Risk Factors” in the Company’s Securities and Exchange Commission filings, including in the Company’s annual and quarterly reports. There may be events in the future that the Company is unable to predict, or over which it has no control, and its business, financial condition, results of operations and prospects may change in the future. The Company assumes no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made unless the Company has an obligation under U.S. federal securities laws to do so.
Investor Contact
Peter Vozzo
ICR Westwicke
(443) 377-4767
Peter.Vozzo@westwicke.com
Media Contact
Terri Clevenger
ICR Westwicke
(203) 856-4326
Terri.Clevenger@westwicke.com
FAQ
What is Plus Therapeutics presenting at the AACR 2022 Annual Meeting?
When is Plus Therapeutics' poster presentation scheduled during AACR 2022?
Where will Plus Therapeutics present their poster at AACR 2022?
What is the significance of Plus Therapeutics' research presented at AACR 2022?
